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Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by 
thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) 
antibodies. There is sound evidence that aPL act as pathogenic autoantibodies being 
responsible for vascular clots and miscarriages. However, the exact mechanisms involved 
in the clinical manifestations of the syndrome are still a matter of investigation. In particular, 
while vascular thrombosis is apparently not associated with inflammation, the pathogen-
esis of miscarriages can be explained only in part by the aPL-mediated hypercoagulable 
state and additional non-thrombotic effects, including placental inflammation, have been 
described. Despite this difference, evidence obtained from animal models and studies in 
APS patients support the conclusion that complement activation is a common denomi nator 
in both vascular and obstetric APS. Tissue-bound aPL rather than circulating aPL-beta2 
glycoprotein I immune complexes seem to be responsible for the activation of the classical 
and the alternative complement pathways. The critical role of complement is supported 
by the finding that complement-deficient animals are protected from the pathogenic effect 
of passively infused aPL and similar results have been obtained blocking complement 
activation. Moreover, elevated levels of complement activation products in the absence 
of abnormalities in regulatory molecules have been found in the plasma of APS patients, 
strongly suggesting that the activation of complement cascade is the result of aPL binding 
to the target antigen rather than of a defective regulation. Placental complement deposits 
represent a further marker of complement activation both in animals and in patients, and 
there is also some suggestive evidence that complement activation products are deposited 
in the affected vessels. The aim of this review is to analyze the state of the art of complement 
involvement in the pathogenesis of APS in order to provide insights into the role of this 
system as predictive biomarker for the clinical manifestations and as therapeutic target.
Keywords: complement, antiphospholipid syndrome, anti-beta2 glycoprotein i antibodies, thrombosis, 
miscarriages, animal models, inflammation, therapy
iNtrODUctiON
In recent years, major efforts have been made to define the molecular mechanisms responsible for 
the clinical manifestations of antiphospholipid syndrome (APS) including vascular thrombosis and 
adverse pregnancy outcomes (1–3). Blood clots can occur in both venous and arterial vessels with 
preferential localization in the brain and coronary arteries, although other vascular districts can 
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also be involved. Vascular thrombosis mediated by beta2 glyco-
protein I (β2GPI)-dependent antiphospholipid antibodies (aPL) 
represents the main pathogenic mechanism that is responsible 
for the major clinical manifestations of the syndrome and it has 
been suggested to be the cause also for other non-classification 
clinical events (4).
Pregnancy morbidity manifests as unexplained deaths of a 
morphologically normal fetus at or beyond the 10th week of ges-
tation, eclampsia, or severe preeclampsia, particularly early, severe 
preeclampsia (5). Although it is clear that the specific antigenic 
reactivity of aPL and their targeting to the placenta are critical 
to produce their effect, pathogenic mechanisms that damage the 
fetal–maternal unit and cause abnormal placental development 
are incompletely understood (6). Indeed, the in  vivo antigenic 
targets of lupus anticoagulant (LA), the strongest risk factor for 
adverse pregnancy outcomes in APS patients, are not known (7). 
While blood clotting represents the main clinical manifestation 
of vascular APS, non-thrombotic mechanisms have been sug-
gested to be a more important cause of defective placentation 
characteristic of the syndrome (1). Moreover, although most pati-
ents display both manifestations, isolated vascular or obstetric 
variants can also be found and there is some discussion as to 
whether vascular and obstetric APS are the same disease (8).
Despite the fact that not all the animal models of aPL-mediated 
fetal loss display inflammatory signature at the placental level, 
inflammation has been suggested to play a role in APS miscar-
riages (9). Analysis of human placental tissues has not clarified 
this issue, since an inflammatory infiltrate was reported in the 
decidua only in some but not all studies. No sign of inflammation 
was observed in the vessel wall of human tissues at variance with 
the findings in obstetric APS. However, endothelial perturbation 
with the expression of a pro-thrombotic and pro-inflammatory 
phenotype was reported in APS models (10).
Complement (C) activation has been shown to be critical 
in APS models, since its blockade protects animals from both 
aPL-mediated clotting and fetal loss (11). In line with the data 
obtained in animal models, C was suggested to be involved in 
vascular APS following the observation of increased plasma levels 
of activation products and reduced C3 and C4 levels or CH50 
activity in some patients (12–18).
Similar findings were reported in obstetric APS and C deposits 
were detected at placental level in some but not all studies 
(19–21). Moreover, the beneficial effect of eculizumab, a human 
monoclonal antibody that prevents C activation by neutralizing 
C5, observed in individual cases further supports the role of C 
activation in human APS (22).
cOMPLeMeNt AND vAscULAr APs
Anecdotal reports revealed the involvement of C in vascular APS 
many years before the sound evidence of C contribution to both 
fetal loss and thrombosis models. Low serum levels of C4 were 
reported in a patient with thrombosis, miscarriages, and aPL, 
and C4 null alleles and low C3/C4 were found to be associated 
with aPL in systemic lupus erythematosus (SLE) patients (12, 14). 
Moreover, the suggestion that C is involved in APS was strongly 
supported by the demonstration of increased plasma levels of 
soluble C5b-9 in nearly 40% of a small series of APS patients with 
stroke (13).
Despite these early reports, no further studies on C activation 
in vascular APS have been carried out for a long time. Oku et al. 
reported reduced serum levels of C3, C4, and decreased CH50 
activity in a small series of primary APS (PAPS). C consumption 
was associated with increased levels of the activation products 
C3a, C4a but not C5a in the absence of reduction of regulatory 
proteins factor H and I suggesting an enhanced turnover rather 
than a defective C regulation (15). However, no clear relation-
ship was found between this finding and clinical or serological 
APS parameters (15). Similar increase in plasma levels of the 
C activation products Bb and C3a were reported by other groups 
in large series of patients with both vascular and obstetric PAPS 
(16, 18). The plasma levels of C3a were also found to be higher 
in another small series of persistently LA positive patients with no 
correlation with thrombosis (17). Moreover, we recently observed 
a significant increase in platelet- and red blood cell-bound C4d 
in PAPS in comparison to SLE and healthy controls further 
supporting the occurrence of C activation in the syndrome (23). 
C consumption and release of C activation products have been 
reported in a case of catastrophic APS (CAPS) (24).
The mechanism responsible for C activation has not been clari-
fied. In one study, circulating immune complexes (CIC) found 
in a high proportion of PAPS patients have been suggested to trig-
ger the classical pathway (15). The prevalence of CIC in APS was 
much lower in other studies suggesting that additional mecha-
nisms may be responsible for C activation (16, 25). However, 
the issue is still a matter of research due to technical problems in 
detecting CIC.
C activation in the fluid phase can be associated with C 
deposition at tissue level, but few reports have been published 
documenting localization of tissue-bound C in APS patients. 
Immunoglobulin (Ig), C1q, and C3 deposits were described in 
the heart valve leaflets from patients with aPL-related valvulopa-
thy (26), and Ig, C1q, and C3 have also been found in kidney 
biopsies from some but not all patients with APS nephropathy 
(27). Altogether, these findings suggest that aPL-mediated C 
activation can take place in the tissues of patients affected by this 
syndrome. We recently reported the case of a PAPS patient with 
arterial popliteal thrombosis who underwent arterial surgical 
bypass. Deposits of C1q, C4, C3, and C5b-9 co-localizing with 
β2GPI and IgG were found in the affected artery wall together 
with increased plasma levels of C5a and C5b-9. Interestingly, 
a short treatment with eculizumab resulted in a substantial 
decrease in the C5a and C5b-9 levels. Overall, these findings 
strongly suggest that C activation takes place in vascular APS 
and that C deposition at the anatomical site of thrombosis plays 
a key role in aPL-mediated clotting (28).
tHe rOLe OF cOMPLeMeNt iN MODeLs 
OF vAscULAr APs
Animal models of vascular APS have been instrumental in estab-
lishing the pathogenic role of antibodies to β2GPI in the forma-
tion of thrombi and the mechanism of their action. The model 
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has been reproduced in various animal species including mice, 
hamsters, and rats using different experimental approaches.
APL-treated mice have been used extensively to monitor the 
development of thrombi in the femoral vein after a pinch injury 
(10). A somewhat similar approach was adopted in hamsters and 
mice that received monoclonal or patients’ antibodies to β2GPI, 
respectively, to induce clot formation in the carotid artery (hamster) 
or cremaster muscle microcirculation (mice) injured either by 
a photochemical reaction (29) or following laser exposure (30). 
Both approaches rely on mechanical or chemical vascular dam-
age to initiate the coagulation process that is further enhanced by 
the administration of aPL resulting in enlargement of the blood 
clot. We followed a different strategy establishing a rat model that, 
in our view, reflects more closely the situation in the clinic (31). 
The model consisted of priming the animals with an amount of 
LPS, that does not induce thrombosis, followed by administra-
tion of aPL. Formation of thrombi in the mesenteric microvessels 
containing arterioles, capillaries, and postcapillary venules was 
monitored by optical imaging. This approach allowed us to firmly 
establish that aPL was totally ineffective in naïve animals and that 
the pro-coagulant effect of these antibodies required a second 
hit provided by LPS that was not needed for their proabortive 
activity.
Despite the different experimental approaches in the mouse 
and rat models of vascular thrombosis, blockade of C activa-
tion with a neutralizing antibody to C5 was shown to prevent 
thrombus enlargement in mice (32) or clot formation in rats 
(31) suggesting the important contribution of C to aPL-induced 
promotion of coagulation. The finding that aPL fail to exert a 
pro-coagulant effect in C3- and C5-deficient mice is consistent 
with the conclusion that C plays a critical role in mediating the 
damaging effect of the antibodies (32). However, there is a major 
difference in the mechanisms of C-mediated pregnancy loss and 
vascular thrombosis. While C5a has been shown to play a major 
role in causing adverse pregnancy outcome induced by aPL (33), 
blood clot formation is apparently dependent on the action of 
the terminal complex C5b-9, as suggested by the failure of aPL 
to promote thrombosis in C6-deficient rats and mice (31, 34). 
Deposition of C9 at sites of localization of IgG on the endothe-
lium of the mesenteric microvessels of rats treated with aPL is a 
clear indication that C activation proceeds till the assembly of 
the membrane attack complex. We and others have provided 
evidence that the terminal complex either in a sublytic or cytoly-
tically inactive form can stimulate endothelial cell to express on 
their surface tissue factor that triggers the extrinsic pathway of 
coagulation (35, 36).
cOMPLeMeNt AND OBstetric APs
Studies in humans support the role of C in aPL-associated preg-
nancy complications. Mild hypocomplementemia and low C3, 
C4 levels were reported in some studies including aPL-positive 
patients with no other associated systemic autoimmune diseases 
(16, 37–39). Although this finding is suggestive for C involvement 
in aPL-mediated miscarriages, C activity was not reduced in all 
pregnant women and a clear relationship with pregnancy compli-
cations was not supported by statistical analysis. Interpretation of 
C levels in pregnant women is difficult because they reflect both 
increased synthesis stimulated by estrogens and consump tion 
(40). To obtain a correct information on the C levels in aPL-
positive pregnant women, the data should be compared with 
those found in normal pregnant controls, but this comparison 
was made only in one study (38).
More recently, increased plasma levels of the activation prod-
ucts Bb and C5b-9 were reported in women with aPL and adverse 
pregnancy outcome suggesting the contribution of C activated 
through the alternative pathway to the pathogenesis of this 
clinical condition (41). The activation products are considered 
a more sensitive marker of C activation, and may contribute to 
promote leukocyte recruitment/activation and release of pro-
inflammatory and anti-angiogenic mediators responsible for 
placental damage. Deposition of C4d and to some extent of C3d 
in term placentas was reported in aPL women in two studies 
further suggesting the contribution of C activation to placental 
impairment mediated by aPL (19, 21).
cOMPLeMeNt DePOsitiON ON HUMAN 
PLAceNtAs FrOM APs PAtieNts
While the finding of C activation products in the circulation of 
patients with obstetric APS is suggestive of C involvement in the 
pathogenesis of adverse pregnancy outcome, there is no doubt 
that the detection of these products in placenta provides more 
direct evidence for C contribution to tissue damage. Search for C 
deposits should of course be restricted to placentas from patients 
with PAPS to avoid confounding results that may derive from 
the analysis of tissue from patients with secondary APS associ-
ated with C-mediated disorders such as SLE. C localization was 
investigated in term placentas from patients with aPL antibodies 
by Shamonki and colleagues (19), who focused their analysis on 
the deposits of C4d, C3b, and C5b-9 complex. They reported 
the presence of these C activation products in the cytoplasm 
of villous trophoblast and on extravillous trophoblast, but it is 
unclear whether there was a preferential cytoplasmic localization 
also in these cells. Histologic examination of placentas revealed 
pathological lesions including decidual vasculopathy, increased 
syncytial knots, and villous infarcts, that were correlated with 
increased C4d staining of villous trophoblast. Surprisingly, the 
presence of C5b-9 in the cytoplasm of villous trophoblast was 
significantly lower suggesting that this complex may not con-
tribute to tissue damage. In addition, the degree of C3b and 
C5b-9 deposition in extravillous trophoblast of placentas from 
aPL-positive patients was not significantly different from that 
found in control placentas raising the question of the relevance 
of these observations to the pathogenic role of C in aPL-mediated 
alterations in maternal decidua.
Our group has conducted a prospective study on 13 preg-
nancies in 11 patients with PAPS, who were under treatment with 
low molecular weight heparin (100 IU/kg/day s.c.) and low dose 
aspirin (100 mg/day). The majority of these patients (10 out 13) 
had medium to high titers of anti-β2GPI and positive LA. The 
pregnancies resulted in eight live births at gestational ages ranging 
between 30 and 38  weeks, one abortion and four fetal loss 
tABLe 1 | Clinical characteristics of the PAPS patients examined for placental C deposits.
Patients Diagnosis LA acL igG/igM anti-β2GPi igG/igM Outcome therapy
BAC 1 PAPS Pos High/high High/high Fetal loss < 10 weeks LMWH/ASA
BAC 2 PAPS Pos High/high High/high Fetal loss > 10 weeks (twins) LMWH/ASA
BAC 3 PAPS Pos High/high High/high Live baby 35 weeks LMWH/ASA/ivIg/CS
BA PAPS Pos High/high High/high Fetal loss > 10 weeks LMWH/ASA
TD PAPS Neg Med/low Med/neg Live baby 38 weeks LMWH/ASA
SA PAPS Pos nd nd Fetal loss > 10 weeks ASAa
SE PAPS Pos High/high High/med Live baby 30 weeks LMWH/ASA
PA PAPS Pos High/high nd Fetal loss > 10 weeks Noneb
FO PAPS Neg High/neg High/neg Live baby 38 weeks LMWH/ASA
BO PAPS Pos Neg/neg Neg/neg Live baby 35 weeks LMWH/ASA
PU PAPS Pos High/neg High/med Live baby 38 weeks LMWH/ASA
AC PAPS Neg High/neg High/med Live baby 33 weeks LMWH/ASA
BL PAPS Pos High/med High/med Live baby 31 weeks LMWH/ASA
PAPS, primary antiphospholipid syndrome (5); C, complement; LA, lupus anticoagulant; aCL, anti-cardiolipin antibodies; anti-β2GPI, anti-beta2 glycoprotein I antibodies;  
LMWH, low molecular weight heparin; ASA, aspirin; ivIg, intravenous immunoglobulins; CS, corticosteroids; nd, not detected.
aThe patient was classified as aPL-positive asymptomatic carrier, and her first pregnancy was treated with ASA only.
bThe patient was not treated with the standard therapy because the positivity for aPL was found after the abortion.
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after 10 weeks’ gestation (Table 1). The study was approved by 
the Istituto Auxologico Italiano Ethics Committee (22-07-2010) 
and patients gave their written informed consent.
Decidual vasculopathy and intervillous thrombi were the most 
common histologic findings observed in PAPS placentas while 
inflammation was less frequent and was seen in both PAPS and 
control placentas, as were also villitis and villous infarcts equally 
detected in both groups of placentas. Deposits of C components 
and C activation products were found in all PAPS placentas 
examined with some variation in the degree of C deposition. 
C1q, C4, and C3 were detected on the decidual endothelium 
vessels at sites of IgG and IgM deposition while C5b-9 showed a 
prevalent subendothelial distribution (Figure 1). Analysis of the 
villi revealed the presence of IgG, IgM, C1q, C4, C3, and C5b-9 
on the surface of syncytiotrophoblast with additional distribution 
of IgM and C5b-9 on intervillous fibrin deposits and of IgG and 
C3 on the endothelium of villous vessels (Figure 2). Interestingly, 
C activation occurred in placental tissue of APS patients despite 
heparin treatment. This was a surprising finding because heparin 
was shown by Girardi and colleagues (42) to inhibit C activation 
and to prevent pregnancy loss in a mouse model of obstetric 
APS. C localization in decidua and villi of control placentas was 
negligible with the only exception of C1q detected on decidual 
endothelium and on extravillous trophoblast confirming previous 
observation that C1q is constitutively expressed in these cells 
in physiological pregnancy (43–45). Altogether, these findings 
support the conclusion that C activation in APS placenta is 
activated by aPL antibodies and justify a possible pathogenic 
role of C activation in fetal loss documented in this study and in 
murine models of APS. However, the presence of C deposits in 
placentas from patients who have had live births is more difficult 
to interpret. It is possible that the damaging effect of C activation 
on placental tissue that affects pregnancy outcome depends on 
the extent and distribution of C deposits in APS placenta. Binding 
of C activation products to restricted placental areas may cause 
tissue alterations that marginally affect the regular progression 
of pregnancy.
tHe rOLe OF cOMPLeMeNt iN ANiMAL 
MODeLs OF PreGNANcY
The initial observation by Branch and colleagues (46) that pas-
sive infusion of serum IgG from patients with aPL induced an 
increased rate of fetal resorptions in pregnant mice was the first 
evidence that suggested a role of the antibodies in the patho-
genesis of fetal loss. These findings and similar data obtained by 
other groups (47, 48) led to the conclusion that obstetric APS is 
a clinical disorder mediated by antibodies that are preferentially 
directed against β2GPI (4). The high degree of protein sequence 
homology between human and animal β2GPI explains the ability 
of human antibodies to cause fetal demise in mice. The β2GPI 
molecule has been found to be localized in the placenta of 
preg nant mice in the absence of antibodies with a prevalent 
distribu tion on syncytio and extravillous trophoblasts, and deci-
dual endothelial cells (49). In vitro experiments have shown that 
aPL interacting with the target molecule expressed on trophoblast 
impair several functions of these cells including proliferation, 
syncitia formation, invasion into maternal deciduas, as well as 
secretion of chorionic gonadotrophin and growth factors (1, 50). 
However, the in vivo relevance of these observations to placental 
dysfunction is unclear as the administration of aPL to C3- 
deficient pregnant mice has no adverse impact on the progres-
sion of pregnancy while resulting in an increased rate of fetal 
loss and growth retardation in wild-type animals (51). These 
data argue for a major role of C activated by aPL in inducing 
adverse pregnancy outcome, a conclusion which is also supported 
by the ability of the C3 convertase inhibitor Crry to prevent 
aPL-mediated fetal loss (51).
Further analysis of the critical step of the C sequence involved 
in this pathological process points to C5 as the key component 
based on the finding that aPL failed to increase fetal resorption 
rate in C5-deficient mice and in animals treated with anti-C5 
antibodies (33). Similar results were obtained in C4 and factor 
B-deficient mice suggesting that C activation is triggered by aPL 
through the classical pathway and is further amplified through 
FiGUre 2 | Immunoperoxidase staining of representative placental villi from a primary antiphospholipid syndrome patient showing deposition of immunoglobulin (Ig) 
and various C components (20× magnification).
FiGUre 1 | Immunoperoxidase staining of a representative placental decidua from a primary antiphospholipid syndrome patient showing deposition of 
immunoglobulin (Ig) and various C components (20× magnification).
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the alternative pathway (52). As activation of C5 results in the 
release of the small pro-inflammatory peptide C5a and the 
large fragment C5b that initiates the assembly of the terminal 
complex C5b-9, experiments conducted to clarify their relative 
contribution to fetal damage have led to the identification of C5a 
as the main mediator of fetal injury. The effect of C5a has been 
attributed to its ability to interact with C5aR expressed on PMN 
and to stimulate the release of TNF-α that induces apoptosis of 
cytotrophoblasts and promotes inflammation (53, 54). C5a was 
also found to induce expression of tissue factor in PMN that 
contributes to favor decidual inflammation and in turn increased 
fetal loss (55). The terminal complex does not seem to play a role 
in aPL-mediated fetal injury as C6-deficient mice had a similar 
rate of pregnancy loss as wild-type mice.
tHerAPeUtic PersPectives
A wealth of experimental and clinical data have clearly shown that 
C is implicated in the pathogenesis of the clinical manifestations 
of APS and have led to the suggestion that this syndrome should 
be considered a C-dependent disorder (31, 54). Despite the large 
body of evidence mainly obtained from animal models support-
ing this conclusion, antibodies or other reagents neutralizing C 
have not been regarded as first-line treatment to prevent adverse 
pregnancy outcome or thrombus formation. One possible expla-
nation is that anticoagulants and low-dose aspirin have been 
used successfully to prevent vascular thrombosis and pregnancy 
abnormalities and there is a general consensus on their use in 
the primary treatment of APS patients. However, it is worth 
mentioning that this type of therapy is not always effective and 
does not always prevent recurrences of obstetric and vascular 
complications particularly in patients with triple positivity for 
LA, anti-cardiolipin, and anti-β2GPI antibodies (56). There are 
some suggestions that the overall therapeutic efficacy of anti-
coagulants can be increased by a combined treatment with other 
drugs, although specific clinical trials are still lacking (22).
Several case reports have been published describing patients 
with CAPS who have benefited from eculizumab administration 
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with a substantial amelioration of their clinical manifestations 
and successful kidney transplantations have also been published 
(22, 57). Similar beneficial results were obtained blocking C acti-
vation in APS patients with multiple arterial thrombosis refrac-
tory to standard therapy (58). It must be pointed out that chronic 
administration of eculizumab would be an expensive therapy to 
prevent thrombus formation due to the high cost of treatment 
to avoid an unpredictable event. This therapeutic measure can 
satisfactorily be restricted to situations in which blood clots are 
more likely to occur. We have shown that eculizumab adminis-
tered to an APS patient prior to femoro-popliteal bypass surgery 
aimed at removing arterial occlusion was effective in preventing 
re-thrombosis (28). As surgical intervention represents the sec-
ond hit required for thrombus formation in APS patients with 
circulating aPL, eculizumab would be expected to have a 
bene ficial effect in patients undergoing vascular surgery. One 
clinical trial is ongoing to assess the efficacy of eculizumab 
in the prevention of APS-associated thrombotic microangi-
opathy following renal transplantation (Clinical Trial.gov #: 
NCT01029587).
Pregnancy is more frequently susceptible to complications in 
APS patients as this condition provides by itself a second hit in 
addition to anti-β2GPI antibodies. Fortunately, a large propor-
tion of APS pregnant women responds to the combination of 
heparin and low dose aspirin, but approximately 20% are resist-
ant to the standard therapy (22). These patients and in particular 
those with a history of recurrent abortions may preferentially 
respond to treatment with C5-neutralizing antibody. Recent data 
have excluded any adverse effect of eculizumab on fetus as only a 
negligible amount of antibody administered to pregnant women 
crosses the placenta leaving the C activity of the newborn largely 
unaffected (58, 59). We propose an alternative option based on 
the use of a human anti-β2GPI monoclonal antibody that targets 
the antigen highly expressed on syncytiotrophast, extravillous 
trophoblast, and decidual endothelial cells and is functionally 
ineffective being unable to activate C (60).
cONcLUsiON
Experimental and clinical data accumulated over recent years 
support the conclusion that the C system is a key factor in the 
pathogenesis of the clinical manifestations of both vascular and 
obstetric APS. In fact, all the in  vivo models and the reports 
from human studies clearly showed C activation; on the other 
hand, in  vitro experimental models demonstrated that aPL 
may directly affect tissue targets or coagulation factors. Further 
studies are warranted to establish if C activation products should 
be considered useful markers to monitor disease severity and 
also if C neutralization should be included as first-line therap-
eutic option in APS patients with CAPS or scheduled for organ 
transplant or different vascular surgical procedures.
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